ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough head and neck cancers
Disease control CompletedThis study tested a new treatment for people with advanced or recurrent head and neck cancer that cannot be cured with standard treatments. It combined a short, intense course of radiation (quad-shot) with immunotherapy drugs that help the immune system fight cancer. The goal was…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, duvelisib and docetaxel, in 26 people with head and neck cancer that had come back or spread and could not be cured. The goal was to see if the combo could shrink tumors. Participants had already tried a type of immunotherapy called a…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Experimental shot targets tumors in Late-Stage cancers
Disease control CompletedThis early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab. It included 6 adults with advanced head and neck, melanoma, or triple-negative breast cancer that had spread. The goal was to see if the combinat…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated May 14, 2026 12:02 UTC